Diverse Psychotomimetics Act Through a Common Signaling Pathway

Science

Volumn 302, Issue 5649, 2003, Pages 1412-1415

  Svenningsson, Per ^a   Tzavara, Eleni T ^b   Carruthers, Robert ^a   Rachleff, Ilan ^a   Wattler, Sigrid ^c   Nehls, Michael ^c   McKinzie, David L ^b   Fienberg, Allen A ^a,d   Nomikos, George G ^b   Greengard, Paul ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

^d Intra Cellular Therapies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION; ENZYME KINETICS; GLYCOLS; PHOSPHATES; PROTEINS;

POINT MUTATIONS;

DRUG PRODUCTS;

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOGEN SYNTHASE KINASE 3; LYSERGIDE; PHENCYCLIDINE; PHOSPHOPROTEIN DARPP 32; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN C FOS; PSYCHEDELIC AGENT; SEROTONIN AGONIST;

DRUG DEVELOPMENT; PSYCHOLOGICAL PHENOMENA; SIGNALING;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GENE DELETION; INHIBITION KINETICS; MOUSE; NEWBORN; NONHUMAN; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CORPUS STRIATUM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FRONTAL LOBE; GENES, FOS; GLYCOGEN SYNTHASE KINASE 3; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PHENCYCLIDINE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTORS, DOPAMINE D1; RNA, MESSENGER; SIGNAL TRANSDUCTION; STARTLE REACTION; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0344443812     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1089681     Document Type: Article

References (21)

1. A. Sawa, S. H. Snyder, Science 296, 692 (2002).
2. A. Carlsson et al., Annu. Rev. Pharmacol. Toxicol. 41, 237 (2001).
3. F. X. Vollenweider, Pharmacopsychiatry 31, 92 (1998).
4. K. F. Berman, B. P. Illowsky, D. R. Weinberger, Arch. Gen. Psychiatry 45, 616 (1988).
5. D. A. Silbersweig et al., Nature 378, 176 (1995).
6. A. Abi-Dargham et al., Am. J. Psychiatry 155, 761 (1998).
7. E. Shaw, D. W. Wooley, Science 124, 121 (1956).
8. E. D. Luby, B. D. Cohen, G. Rosenbaum, J. S. Gottlieb, R. Kelley, Am. Med. Assoc. Arch. Neurol. Psychiatry 81, 363 (1959).
9. S. H. Snyder, Am. J. Psychiatry 130, 61 (1973).
10. P. Greengard, Science 294, 1024 (2001).
11. M. A. Geyer, K. Krebs-Thomson, D. L. Braff, N. R. Swerdlow, Psychopharmacology 156, 117 (2001).
12. R. M. Ridley, Prog. Neurobiol. 44, 221 (1994).
13. B. K. Lipska, D. R. Weinberger, Neuropsychopharmacology 10, 199 (1994).
14. H. C. Hemmings Jr., P. Greengard, H. Y. L. Tung, P. Cohen, Nature 310, 503 (1984).
15. J. A. Girault, H., C. Hemmings Jr., K. R. Williams, A. C. Nairn, P. Greengard, J. Biol. Chem. 264, 21748 (1989).
16. F. Desdouits, J. C. Siciliano, P. Greengard, J.-A. Girault, Proc. Natl. Acad. Sci. U.S.A. 92, 2682 (1995).
17. J. A. Bibb et al., Nature 402, 669 (1999).
18. P. Svenningsson, R. Carruthers, I. Rachleff, P. Greengard, unpublished observations.
19. R. S. Jope, G. N. Bljur, Mol. Psychiatry 7, S35 (2002).
20. F.-C. Liu, A. M. Graybiel, Neuron 17, 1133 (1996).
21. 130 DARPP-32, and DARPP-32 antibodies; and K. Knitkowski and J. Camara for technical assistance.